References

• 1.

  UNAIDS. Forthcoming publication, July 2012.

• 2.

  United Nations. United Nations High Level meeting on AIDS [online] 2011, June 10 [cited 2011, June 22] Available from: http://www.un.org/en/ga/aidsmeeting2011/documents.shtml

• 3.

  Shwartländer B, Stover J, Hallett, et al. Towards an improved investment approach for an effective response to HIV/AIDS.[Online] Lancet. June 2011. 377, 9782:2031-2041. [cited 2012 June 25] Available from: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60702-2/abstract

• 4.

  Cohen M, Chen Y, McCauley M, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. The New England Journal of Medicine. August 11, 2011 365:493-505.

• 5.

  World Health Organization. Guidance on Couples HIV Testing and Counselling including Antiretroviral Therapy for Treatment and Prevention in Serodiscordant Couples. [Online] April 2012. [cited 2012 June 25] Available from: http://www.who.int/hiv/pub/guidelines/9789241501972/en/

• 6.

  World Health Organization. Programmatic Update. Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. [Online] April 2012 [cited 2012 June 25] Available from: http://www.who.int/hiv/pub/mtct/programmatic_update2012/en/

• 7.

  World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. [Online] 2006 Revision. Health (San Francisco), 2006. [cited 2012 June 25] Available from: http://www.who.int/hiv/pub/arv/adult/en/

• 8.

  European Medicines Agency. Outcome of a renewal procedure. Questions and
  answers on the review of Zerit (stavudine). [Online]. 2011. [Cited 2011 Apr 8] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/human/000110/WC500102227.pdf

• 9.

  Médecins Sans Frontières. Speed up scale-up: Strategies, Tools and Policies to Get the Best HIV Treatment to More People, Sooner. Forthcoming publication, July 2012.

• 10.

  Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and metaanalysis. AIDS, 2011, 25(18):2308211;2304.

• 11.

  World Health Organization. Technical update on treatment optimization: use of efavirenz during pregnancy in a public health perspective. [Online] World Health Organization, Geneva, June 2012. [Cited 2012 June 25]. Available from: http://whqlibdoc.who.int/publications/2012/9789241503792_eng.pdf

• 12.

  Stover J. Forecasting Demand for ARVs 2011-2012. [online] Geneva, Switzerland. 2011, February 15. [cited 2011, June 15] Available from: http://www.who.int/entity/hiv/amd/pfi_forecasting_demand_arvs_j_stover.pdf

• 13.

  World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2010 Revision.[Online] Health (San Francisco), 2010.
  [Cited 2012 June 25] Available from: http://www.who.int/hiv/pub/arv/adult2010/en/index.html

• 14.

  Calmy A, Ford N, Hirschel B, et al. HIV Viral Load Monitoring in Resource-Limited Regions: Optional or Necessary? [Online] Clinical Infectious Diseases 44, no. 1 (2007): 128. [Cited 2012 June 25] Available from: http://cid.oxfordjournals.org/content/44/1/128.short

• 15.

  The Global Fund to Fight AIDS, Tuberculosis and Malaria. Price and Quality Reporting Tool. [Online] 2012 [Cited 2012 May 20] Available from: http://www.theglobalfund.org/en/procurement/pqr/

• 16.

  The Global Fund to Fight AIDS, Tuberculosis and Malaria. Price and Quality Reporting Tool. [Online] 2012
  [Cited 2012 January 24] Available from: http://bi.theglobalfund.org/analytic/saw.dll?Dashboard&_scid=8QxAKn3Svx4

• 17.

  Médecins Sans Frontières, Solidarité thérapeutique hospitalière en réseau (Esther), and Solidarité thérapeutique contre le sida (SOLTHIS). Antiretroviral Sequencing Meeting Report. [Online] 22/23 September 2011, Geneva Switzerland. [Cited 2012 June 25] Available from: http://www.msfaccess.org/content/antiretroviral-sequencingmeeting-report

• 18.

  Calmy A, Klement E, Teck R, et al. Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling up. AIDS 2004.18:2353-60.

• 19.

  Kranzer K, Ford N. Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review. Trop Med Int Health. 2011 Jul 1.

• 20.

  Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006 Nov;3(11):e438.

• 21.

  Ford N, Calmy A. Improving first-line antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS. 2010. 1:38-47.

• 22.

  Moon S, Jambert E, Childs M and von Schoen-Angerer T. A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries. [Online] Globalization and Health 2011, 7:39 [cited 2012 June 17]. Available from: http://www.globalizationandhealth.com/content/pdf/1744-8603-7-39.pdf

• 23.

  Waning B, Diedrichsen E & Moon S. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries. 2010. Journal of the International AIDS Society, 13:35.

• 24.

  World Trade Organization. Uruguay Round Agreement: Trade-related Aspects of Intellectual Property Rights. [Online] 1994, April 15. [Cited 2012 June 6] Available from: http://www.wto.org/english/docs_e/legal_e/27-trips_01_e.htm

• 25.

  Médecins Sans Frontières Access Campaign. India Issues First Compulsory Licence. Press Release. [Online] 2012, March 12, New Delhi/Geneva [Cited 2012 June 7] Available from: http://www.msfaccess.org/resources/pressreleases/1780

• 26.

  Médecins Sans Frontières. MSF review of the July 2011 Gilead licences to the Medicines Patent Pool [Online] December 2011. [cited 2012 May 2]. Available from http://www.msfaccess.org/content/msfreview-july-2011-gilead-licences-medicinespatent-pool

• 27.

  Correa C. Pharmaceutical Innovation, Incremental Patenting and Compulsory Licensing, [Online]. 2011. [cited 2012 June 17]. Available from: http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=webcd=1&ved=0CEoQFjAA&url=http%3A%2F%2Fwww.law.fsu.edu%2Fevents%2Fdocuments%2FCorrea.docx&ei=QefdT4DYNIX0-gai-7X7CQ&usg=AFQjCNHHuRKgUuHlEYeBLOxA18ziMVsEKA

• 28.

  Elliott R. First Test of WTO Mechanism for Procuring Generic Medicines under Compulsory License, via Canada’s Access to Medicines Regime. HIV/AIDS Policy & Law Review (Canadian HIV/AIDS Legal Network) 12 (2/3), 2007: 23-25.

• 29.

  World Health Organization. Antiretroviral Therapy of HIV Infection in Infants and Children – Recommendations for a Public Health Approach – 2010 revision. [online] Geneva, 2010. [cited 2011, June 10] Available from: http://www.who.int/hiv/pub/paediatric/infants2010/en/index.html

• 30.

  U.S. Food and Drug Administration Drugs@FDA: FDA approved drug products [Online]. [2010?] [cited 2010 May 20]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/

• 31.

  World Health Organization. WHO model list of essential medicines. 17th ed. [Online]. Geneva: WHO; 2011 Mar [cited 2012 May 21]. Available from: http://www.who.int/medicines/publications/essentialmedicines/en/index.html

• 32.

  World Health Organization. WHO Model List of Essential Medicines for Children. 3rd edition [online]. Geneva: WHO; 2011 March [cited 2012 April 19]. Available from: http://www.who.int/medicines/publications/essentialmedicines/en/

• 33.

  GlaxoSmithKline Annual Report 2009: GSK is changing. [Online] Brentford (UK): GlaxoSmithKline; 2010 Mar. Available from: http://www.gsk.com/investors/reps09/GSKReport-2009-full.pdf

• 34.

  GlaxoSmithKline. Annual report 2004: new challenges, new thinking. [Online] Brentford (UK): GlaxoSmithKline; 2005 Mar. Available from: http://www.gsk.com/investors/annual-reports-04.htm

• 35.

  GlaxoSmithKline. Annual report 2005: human being. [Online] Brentford (UK): GlaxoSmithKline; 2006 Mar. Available from: http://www.gsk.com/investors/annualreports-05.htm

• 36.

  GlaxoSmithKline. Annual report 2006: a human race. [Online] Brentford (UK): GlaxoSmithKline; 2007 Mar. Available from: http://www.gsk.com/investors/reps06/annual-report-2006.pdf

• 37.

  GlaxoSmithKline. Annual report 2007: answering the questions that matter. [Online] Brentford (UK): GlaxoSmithKline; 2008 Feb. Available from: http://www.gsk.com/investors/reps07/annual-report-2007.pdf

• 38.

  GlaxoSmithKline. Annual report 2008: grow, deliver, simplify. [Online] Brentford(UK): GlaxoSmithKline; 2009 Mar. Available from: http://www.gsk.com/investors/reps08/GSKReport-2008-full.pdf

• 39.

  European Patent Office: esp@cenet. Therapeutic nucleosides. EP0349242 (A2) [Online]. 1990 Jan 3 [cited 2010 May 20]. Available from: http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP0349242&F=0

• 40.

  European Patent Office: esp@cenet.Chloropyrimide Intermediates. WO9521161 (A1) [Online]. 1995 Aug 10.[cited 2010 May 20]. Available from: http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO1995021161&recNum=1&docAn=GB1995000225&queryString=FP:(WO9521161)&maxRec=1

• 41.

  European Patent Office: esp@cenet. Carbocyclic nucleoside hemisulfate and its use in treating viral infections. WO9852949 (A1) [Online]. 1998 Nov 26 [cited 2010 May 20]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9852949&F=8&QPN=WO9852949

• 42.

  European Patent Office: esp@cenet. Pharmaceutical compositions. WO9939691 (A2) [Online].1998 Aug 12 [cited 2010 May 20]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9939691&F=0&QPN=WO9939691

• 43.

  Amin, T. HIV Drug Patents in China – Full Report. [Online]. Initiative for Medicines, Access & Knowledge 2010 May. [cited 2010 May 20]. Available from: http://www.imak.org/storage/IMAK%20HIV%20Drug%20Patents%20in%20China%20Tahir%20Amin%20May%202010.pdf

• 44.

  Initiative for Medicines, Access and Knowledge (I-MAK). Abacavir sulphate [Online]. 2009 [cited 2010 May 20] Available from: http://www.i-mak.org/abacavir-sulfate/

• 45.

  Médecins Sans Frontières. Blank Cheque for Abuse: ACTA & its Impact on Access to Medicines [Online]. 2012 February. [cited 2012 June 17]. Available from: http://www.msfaccess.org/content/acta-and-its-impact-access-medicines

• 46.

  Indian Patent Office. Patent Number 212734. [Online]. 2007 Dec 14. [cited 2010 May 22]. Available from: http://210.210.88.164/patentgrantedSearch/display/Application.asp?application_number=IN/PCT/2000/193/KOL

• 47.

  Medicines Patent Pool. The Patent Status Database for Selected HIV Medicines. [Online]. [cited 2012 May 2]. Available from: http://www.medicinespatentpool.org/patent-data/patent-status-of-arvs/

• 48.

  Bristol-Myers Squibb. Annual Report 2011. Growth through Innovation. [Online] Bristol-Myers Squibb; 2011. [cited 2012 June 1] Available from: http://investor.bms.com/phoenix.zhtml?c=106664p=irolreportsannual

• 49.

  Bristol-Myers Squibb. Annual Report 2010: Significant changes. Significant results. Our biopharma transformation. [Online] Bristol-Myers Squibb; 2011. [cited 2012, June 1] Available from: http://investor.bms.com/phoenix.zhtml?c=106664&p=irol-reportsannual

• 50.

  Bristol-Myers Squibb. Annual Report 2009: delivering on our commitments. [Online] Bristol-Myers Squibb; 2010. [cited 2012, June 1] Available from: http://thomson.mobular.net/thomson/7/3058/4163/document_0/BMS_AR09.pdf

• 51.

  Bristol-Myers Squibb. Annual report 2008: BioPharma: our strategy in action. [Online] Bristol-Myers Squibb; 2009. [cited 2012 June 1] Available from: http://library.corporateir.net/library/10/106/106664/items/329615/89F48B26-8E28-4566-8F26-AA9133B83124_BMS_AR08.pdf

• 52.

  Bristol-Myers Squibb. Annual report 2007: BioPharma: the next generation. [Online] Bristol-Myers Squibb; 2008. [cited 2012, June 1]. Available from: http://www.bmsa.com.au/documents/2007annualreport.pdf

• 53.

  Bristol-Myers Squibb. Bristol-Myers Squibb Company reports financial results for the fourth quarter and 12 months of 2006 and announces EPS guidance for 2007 [Press release, online]. New York: Bristol-Myers Squibb Company; 2007 Jan 25 [cited 2010 May 21]. Available from: http://www.bms.com/news/press_releases/pages/default.aspx

• 54.

  Will once-daily Kaletra be enough to see off the threat of Reyataz? [Article]. Pharmaceutical Business Review. [online] 2005 May 05. [cited 2010 May 20]. Available from: http://www.hospitalpharma.com/features/feature.asp?ROW_ID=591

• 55.

  European Patent Office: esp@cenet. Antivirally active heterocyclic azahexane derivatives. WO9740029 (A1) [Online]. 1997 Oct 30 [cited 2010 May 20]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9740029&F=8&QPN=WO9740029

• 56.

  European Patent Office: esp@cenet. Bisulfate salt of HIV protease inhibitor. WO9936404 (A1) [Online]. 1999 July 22 [cited 2010 May 21]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9936404&F=8&QPN=WO993640

• 57.

  European Patent Office: esp@cenet. Process for preparing atazanavir bisulfate and novel forms. WO2005108349 (A2) [Online]. 2005 Nov 17 [cited 2010 May 21]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO2005108349&F=8&QPN=WO2005108349

• 58.

  World Intellectual Property Organization. Antivirally Active Heterocyclic Azahexane Derivatives, WO9740029 [Online], 1997 October 30 [cited 2012 June 14]. Available from: http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO1997040029&recNum=1&docAn=EP1997001860&queryString=FP:(WO9740029)&maxRec=1

• 59.

  World Intellectual Property Organization. Bisulfate Salt Of HIV Protease Inhibitor, WO9936404 [Online], 1999 June 22 [cited 2012 June 14]. Available from: http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO1999036404&recNum=1&docAn=US1998027382&queryString=FP:(WO9936404)&maxRec=1

• 60.

  World Intellectual Property Organization. Process for Preparing Atazanavir Bisulfate And Novel Forms, WO2005108349 [Online], 2005 November 17 [cited 2012 June 14]. Available from: http://www.wipo.int/patentscope/search/en/WO2005108349

• 61.

  World Intellectual Property Organization. Tableted compositions containing Atazanavir, WO2009002821[Online], 2008 December 31 [cited 2012 June 14]. Available from: http://www.wipo.int/patentscope/search/en/WO2009002821

• 62.

  World Intellectual Property Organization. Tableted compositions containing Atazanavir, WO2009002829 [Online], 2008 December 31 [cited 2012 June 14]. Available from: http://www.wipo.int/patentscope/search/en/WO2009002829

• 63.

  World Intellectual Property Organization. Tableted compositions containing Atazanavir, WO2009002823 [Online], 2008 December 31 [cited 2012 June 14]. Available from: http://www.wipo.int/patentscope/search/en/WO2009002823

• 64.

  World Intellectual Property Organization. Tableted compositions containing Atazanavir, WO2009002826 [Online], 2008 December 31 [cited 2012 June 14]. Available from: http://www.wipo.int/patentscope/search/en/WO2009002826

• 65.

  Indian Network for People Living with HIV/AIDS, Kartakaka Network for People Living with HIV/AIDS. Pre-grant representation by way of opposition under section 25(1) of the patents act1970(39 of 1970) and rule 55 (1) of the rules as amended by the patents (amendment) act, 2005 against Patent Application No. 805/ MAS/1997 [Online] 1997 April 21 [cited 2012 June 14]. Available from: http://www.scribd.com/doc/57827837/Atazanavir-India-patent-Opposition-8051970

• 66.

  Antivirally Active Heterocyclic Azahexane Derivatives, 805/MAS/1997. [Online]. [cited 2011 June 14] Available from: http://india.bigpatents.org/apps/1I7Bu2qG

• 67.

  Letter from India Patent Office on abandonment of Patent application 805/MAS/1997 [Online] 2007 August 16. [cited 2011 June 14] Available from: http://www.scribd.com/doc/818175/Indiaatazanavirabandoned-letter

• 68.

  Indian Patent Office. Heterocyclic azahexane derivatives. 310/CHE/2007. 2008 Nov 28. [cited 2011 June 14].

• 69.

  Indian Patent Office. Heterocyclic Azahexane Derivatives,3235/CHE/2008. 2008 Dec 22 [cited 2011 June 14].

• 70.

  Indian Patent Office. Process for preparing Atazanavir Bisulfate and Novel Forms, 6425/ DELNP/2006. 2007 August 31 [cited 2011 June 14].

• 71.

  Médecins Sans Frontières. India Rejects Patents for Two Key AIDS Drugs [Online] New Delhi, 2011 January 7 [cited 2012 June 12]. Available from: http://msfaccess.org/about-us/media-room/press-releases/indiarejects-patents-two-key-aids-drugs

• 72.

  Indian Patent Office. Process for preparing Atazanavir Bisulfate and Novel Forms, 2933/DELNP/2009. 2009 December 25 [cited 2011 June 14].

• 73.

  Indian Patent Office. Tableted Compositions Containing Atazanavir, 8524/DELNP/2009. [cited 2011 June 14].

• 74.

  Indian Patent Office. Tableted Compositions Containing Atazanavir, 8332/DELNP/2009. [cited 2011 June 14].

• 75.

  Indian Patent Office. Tableted Compositions Containing Atazanavir, 8330/DELNP/2009. [cited 2011 June 14].

• 76.

  Indian Patent Office. Tableted Compositions Containing Atazanavir, 8328/DELNP/2009. [cited 2011 June 14].

• 77.

  310/CHE/2007. Indian Patent Information Retrieval System. Office of Controller General of Patents Designs, and Trademarks. [Online] India, 2011, June [cited 2011, June 22] Available from: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=310/CHE/2007

• 78.

  BMS Economic Performance. [Online] 2006 [cited 2010 May 20]. Available from: http://www.bms.com/

• 79.

  Bristol-Myers Squibb. Bristol-Myers Squibb Signs New Agreement to Expand Access to Reyataz® (atazanavir sulfate) in sub-Saharan Africa and India. [Press Release]. 2011 June 28. [cited 2012 June 7] Available from: http://www.bms.com/news/press_releases/pages/default.aspx?RSSLink=http://www.businesswire.com/news/bms/20110628005212/en&t=634449380775195037

• 80.

  Information provided by Brazilian Department on DSTs/AIDS and Hepatitis(2010). [cited 2010 June 1].

• 81.

  Cimieri F. Fiocruz pretende produzir maisdois remédios antiaids (Fiocruz intends to produce two more AIDS drugs) [Online] Estado de São Paulo 2009 Feb 17. [cited 2012 June 5] Available from: http://www.estadao.com.br/estadaodehoje/20090217/not_imp325004,0.php

• 82.

  Formenti L. Pacientes com HIV voltam a sofrer com desabastecimento de remédios (HIV patients suffer againg with medicines shortages) [Online] Estado de São Paulo 2011 Mar 17. [cited 2012 June 5] Available from: http://www.estadao.com.br/estadaodehoje/20110317/not_imp693049,0.php

• 83.

  Working Group on Intellectual Property GTPI/Rebrip [Online]. 2011 Apr 4. Available from: http://www.deolhonaspatentes.org.br/media/file/Notas%20GTPI%20-%202011/Carta%20sobre%20desabastecimento%20do%20Atazanavir.pdf

• 84.

  Com PPPs, governo nacionaliza produção de mais 4 remédios (Through PPPs, government nationalizes the
  production of four more medicines). [Online] Valor Economico 2011 Apr 5. [cited 2012 June 5] Available from: http://www.interfarma.org.br/site2/index.php/artigos-enoticias/clipping-do-setor/2416com-pppsgovernonacionaliza-producao-de-mais-4-remedios

• 85.

  Information provided by Brazilian Department on DSTs/AIDS and Hepatitis (April 2011).

• 86.

  United States Food and Drug Administration. Approved and Tentatively Approved Antiretrovirals in Association with the President’s Emergency Plan [Online] 2012 June 20 [cited 2012 June 25] Available from: http://www.fda.gov/InternationalPrograms/FDABeyondOurBordersForeignOffices/AsiaandAfrica/ucm119231.htm

• 87.

  Indian Patent Office, Patent Application Number: 8332/DELNP/2009. [Online] 2009 March 6 [cited 2012 June 4]. Available from:http://ipindia.nic.in/ipr/patent/journal_archieve/journal_2009/pat_arch_032009/official_journal_06032009_part_iv.pdf

• 88.

  Bristol-Myers Squibb. Bristol-Myers Squibb Signs New Agreement to Expand Access to Reyataz® (atazanavir sulfate) in sub-Saharan Africa and India. [Online]. 2011 June 28. [cited 2012 June 8] Available from: http://www.bms.com/news/press_releases/pages/default.aspx?RSSLink=http://www.businesswire.com/news/bms/20110628005212/en&t=634449380775195037

• 89.

  Johnson and Johnson. Annual Report 2010. Celebrating 125 years. [Online] Johnson and Johnson, 2010. [cited 2011, June 16] Available from: http://www.investor.jnj.com/2010annualreport/pdf/2010-annual-report.pdf

• 90.

  Johnson and Johnson. Annual Report 2011. [Online] Johnson and Johnson, 2011. [cited 2012, April 23] Available from: http://www.investor.jnj.com/annual-reports.cfm

• 91.

  European Patent Office: esp@cenet.Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors. WO9404492 (A1) [Online]. 1994 Mar 3 [cited 2010 May 20]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9404492&F=1&QPN=WO9404492

• 92.

  European Patent Office: esp@cenet.Multi-drug resistant retroviral protease inhibitors and associated methods. WO9967254 (A2) [Online]. 1999 Dec 29 [cited 2010 May 20]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9967254&F=0&QPN=WO9967254

• 93.

  Thomson Reuters. Current Patents Gazette, [Online]. 2007, Week 25. [cited 2010 May 22]. Available from: http://thomsonreuters.com/products_services/science/science_products/a-z/current_patents_gazette

• 94.

  The Global Fund. Quality Assurance of Pharmaceutical Products: [online] Geneva, 2010. [cited 2012, June 7] Available from: http://www.theglobalfund.org/en/procurement/quality/pharmaceutical/#General

• 95.

  Prezista (darunavir) [package insert]. Beerse, (Belgium). Janssen Pharmaceuticals Corp; 2012.

• 96.

  World Intellectual Property Organization. Hydroxyethylamino Sulfonamides useful as Retroviral Protease Inhibitors, WO/1994/004492 [Online], 1994 March 3 [cited 2012 June 15]. Available from: http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO1994004492&recNum=1&docAn=US1993007814&queryString=FP:(WO/1994/004492%20)&maxRec=1

• 97.

  Indian Patent Office. Pseudopolymorphic forms of a HIV Protease Inhibitor, 3598/DELNP/2004, 2008 January 1 [cited 2012 June 15].

• 98.

  Indian Patent Office. Methods for the preparation of (3R,3AS, 6AR) hexahydrofuro [2,3-B] Furan-3-OL, 5301/DELNP/2006, 2007 August 03[cited 2012 June 15].

• 99.

  Indian Patent Office. Combination of Cytochome P450 Dependent Protease Inhibitors, 1647/ DELNP/2004, 2007 November 30 [cited 2012 June 15].

• 100.

  Indian Patent Office. Combination of anti-HIV Reverse Transcriptase and Protease Inhibitors, 7958/DELNP/2006. 2007 April 27 [cited 2012 June 15].

• 101.

  Rejection Decision of application for Patent no. 3598/ DELNP/ 2004 [Online] 2009 July 6 [cited 2011 June 15] Available from: India Patent Office http://ipindiaonline.gov.in/decision/3598-%20DELNP-%202004-281/3598-delnp-2004.pdf

• 102.

  Rejection Decision of application for Patent no. 1647/DELNP/2000 [Online] 2009 March 29 [cited 2011 June 15] Available from: http://ipindiaonline.gov.in/decision/1647-DELNP-2000-284/1647-del-2004.pdf

• 103.

  Indian Patent Office. Application No.7958/DELNP/2006 Abandoned U/S 21(1). 2007 April 27 [cited 2011 June 15].

• 104.

  Indian Patent Office. Combination of Cytochome p450 dependent Protease Inhibitors, 2221/ DELNP/2008. 2008 April 25 [cited 2011 June 15].

• 105.

  World Health Organization. Prequalification programme. Available from: www.who.int/prequal

• 106.

  President’s Emergency Plan for AIDS Relief: Approved and Tentatively Approved Antiretrovirals in Association with the President’s Emergency Plan. [Online] US FDA, 2012, June 26 (updated). [cited 2012, July 2]. Available from http://www.fda.gov/InternationalPrograms/FDABeyondOurBordersForeignOffices/AsiaandAfrica/ucm119231.htm

• 107.

  Medicines Patent Pool. US National Institutes of Health (NIH) First to Share Patents with Medicines Patent Pool As it Opens for Business. [Online press release] Geneva, 2010, September 30 [cited 2011, June 24] Available from: http://www.medicinespatentpool.org/content/download/310/2027/version/1/file/Medicines%2BPatent%2BPool%2BNIH%2Blicense%2BPR%2BEMB%2Bfor%2B30%2BSept%2B2010%2BFINAL-1.pdf

• 108.

  Medicines Patent Pool. Statement on J&J’s Decision on Negotiations with the Pool. [Online] 2012 January 31 [cited 2012 May 2]. Available from: http://www.medicinespatentpool.org/statement-on-jjsdecision-on-negotiations/#13

• 109.

  Johnson & Johnson. Tibotec Signs Multiple Agreements with Generic Manufacturers to Provide Access to New
  HIV Treatment. [Online] 2011 January 27 [cited 2012 May 2]. Available from: http://www.jnj.com/connect/news/all/tibotecsigns-multiple-agreements-with-genericmanufacturers-to-provide-access-to-newhiv-treatment

• 110.

  Médecins Sans Frontières. Johnson & Johnson turns its back on people living with HIV/AIDS. [Online] 2011 December 28 [cited 2012 May 2]. Available from: http://www.msf-me.org/en/news/news-media/news-press-releases/johnson-johnson-turnsits-back-on-people-living-with-hivaids.html

• 111.

  Bristol-Myers Squibb. Annual report 2005: every hour, every place. [Online] Bristol-Myers Squibb; 2006. [cited 2012 June 6] Available from: http://library.corporate-ir.net/library/10/106/106664/items/189260/BMY_AR_05.pdf

• 112.

  European Patent Office: esp@cenet. Enteric Coated Pharmaceutical composition and Method of Manufacturing. WO9961002 (A1). [Online]. 1999 Dec 2. [cited 2010 May 20]. Available from: http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=19991202&CC=WO&NR=9961002A1&KC=A1

• 113.

  Pinheiro E, et al. Examining the production costs of antiretroviral drugs. [Online] Aids Intern Soc Journal, volume 20 – Issue 13, 2006 Aug 22. [cited 2012 June 12] Available from: http://journals.lww.com/aidsonline/Abstract/2006/08220/Examining_the_production_costs_of_antiretroviral.8.aspx

• 114.

  Bristol-Myers Squibb. Bristol-Myers Squibb Signs New Agreement to Expand Access to Reyataz® (atazanavir
  sulfate) in sub-Saharan Africa and India.[Online]. 2011 June 28. [cited 2012 June 4] Available from: http://www.bms.com/news/press_releases/pages/default.aspx?RSSLink=http://www.businesswire.com/news/bms/20110628005212/en&t=634449380775195037

• 115.

  Bristol-Myers Squibb. Financial reporting: 2008-2009 financial summary: Bristol-Myers Squibb company worldwide net sales from continuing operations by product quarterly sales trend analysis [Online]. 2009 [cited 2010 May 22]. Available from: http://www.bms.com/Documents/investors/product_sales_2009.pdf

• 116.

  Bristol-Myers Squibb. Financial results for the 4th quarter and 12 months of 2006 and announces EPS guidance for 2007. [Online]. 25 Jan 2007. [cited 2010 May 22]. Available from: http://www.accessmylibrary.com/coms2/summary_0286-29334362_ITM

• 117.

  Bristol-Myers Squibb. Annual report 2005: every hour, every place. [Online] Bristol-Myers Squibb; 2006. [cited 2012 June 11] Available from: http://library.corporate-ir.net/library/10/106/106664/items/189260/BMY_AR_05.pdf

• 118.

  European Patent Office: esp@cenet. Benzoxazinones as inhibitors of HIV reverse transcriptase. CA2101572 (A1) [Online]. 1994 Feb 8 [cited 2010 May 20]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=CA2101572&F=0&RPN=WO9403440&DOC=deb45b02a96924db95500bc28a42e9b960

• 119.

  European Patent Office: esp@cenet. Process for the Crystallization of a Reverse Transcriptase Inhibitor Using an Anti-Solvent. WO 9833782 (A1) [Online]. 1998 Aug 6. [cited 2010 May 22]. Available from: http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EPFT=D&date=19980806&CC=WO&NR=9833782A1&KC=A1

• 120.

  World Intellectual Property Organization. Compositions and methods for combination antiviral therapy. WO/2004/064845 [Online]. 2004 Aug 5 [cited 2010 May 22]. Available from: http://www.wipo.int/pctdb/en/wo.jsp?wo=2004064845

• 121.

  Decision in the Matter of an application for Patent no. 3383/DELNP/2005 – Gilead Sciences vs Cipla. [Online] Gopakumar Nair Associates, India, 2009, March 25 [cited 2011, June 16] Available from: http://www.gnaipr.com/CaseLaws/3383DELNP2005.pdf

• 122.

  Indian Patent Office. Compositions and Methods For Combination Antiviral Therapy, Patent Application No. 6665/DELNP/2008. 2009 October 24 [cited 2012 May 04].

• 123.

  World Intellectual Property Organization. Stable fixed-dose unitary formulations containing tenofovir, A surfactant, efavirenz and emtricitabine. WO/2006/135933 [Online]. 2006 Dec 21 [cited 2010 May 22]. Available from: http://www.wipo.int/pctdb/en/wo.jsp?wo=2006135933

• 124.

  Thailand. Ministry of Public Health and National Health Security Office. Facts and evidences on the 10 burning issues related to the Government use of patents on three patented essential drugs in Thailand: document to support strengthening of social wisdom on the issue of drug patent. [online] Ministry of Public Health and National Health Security; 2007. [cited 2011, June 20] Available from: http://www.moph.go.th/hot/White%20Paper%20CL-EN.pdf

• 125.

  Personal communication with Kannikar Kijtiwatchakul, MSF Thailand. Price quoted in Thai Baht converted to US$ through www.oanda.com [cited 2009 Sep 21].

• 126.

  Brazil. Ministério da Saúde. Departamento de DST, Aids e Hepatites Virais. Brasil declara o medicamento Efavirenz de interesse público (Brazil declares Efavirenz a medicine in the public interest) [Press release]. Brasilia: Departamento de DST, Aids e Hepatites Virais; 2007 Apr 25 [cited 2010 May22]. Available from: http://www.aids.gov.br/data/Pages/LUMISE77B47C8ITEMID252CEA75915C48019A65E5039AFB9560PTBRIE.htm

• 127.

  Treatment Action Campaign. TAC complaint increases access to efavirenz: MSD finally agrees to grant licences on reasonable terms [Online]. 2008 Jun 1 [cited 2010 May 22]. Available from: http://www.tac.org.za/community/node/2329

• 128.

  Gilead Sciences. 2011. Form 10-K. [Online] Foster City (CA): Gilead Sciences Inc; 2012 Feb 23. [Cited 2012 Apr 26]. Available from: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irolreportsAnnual

• 129.

  Gilead Sciences.Form 10-K. [Online] Foster City (CA): Gilead Sciences, Inc.; 2011 Feb 28. [cited 2011 Apr 6]. Available from:
  http://phx.corporate-ir.ne/External.File?item=UGFyZW50SUQ9ODM2NDJ8Q2hpbGRJRD0tMXxUeXBlPTM=&t=1

• 130.

  Gilead Sciences. Gilead Sciences Announces Record Fourth Quarter and Full Year 2009 Financial Results. [Online]. Foster City (CA): Gilead Sciences, Inc.; 2010 Jan 26. [cited 2010 May 22]. Available from: http://www.gilead.com/pr_1379225

• 131.

  Gilead Sciences. 2006 Form 10-K: annual report which provides a comprehensive overview of the company for the past year. [Online] Delaware: Gilead Sciences Incorporated; 2007 [cited 2010 May 22]. Available from: http://www.gilead.com/pdf/GILEADSCIENCESI10K.pdf

• 132.

  Gilead Sciences. Gilead Sciences announces fourth quarter and full year 2007 financial results [Online]. Foster City (CA): Gilead Sciences, Inc.; 2008 Jan 23 [cited 2010 May 22]. Available from: http://www.gilead.com/pr_1099304

• 133.

  Gilead Sciences. Gilead Sciences announces fourth quarter and full year 2008 financial results [Online]. Foster City (CA): Gilead Sciences, Inc.; 2009 Jan 27 [cited 2010 May 22]. Available from: http://www.gilead.com/pr_1248887

• 134.

  European Patent Office: esp@cenet.Substituted -1,3-oxathiolanes with antiviral properties. EP0382526 (A2) [Online].1990 August 16 [cited 2010 May 22]. Available from: http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP0382526&F=0

• 135.

  Thomson Reuters Science. Gazette Journal [Online] 2002. Available from: http://scientific.thomsonreuters.com/media/cdjournals/gazettenews/2002/CPG_News_0224.prf

• 136.

  European Patent Office: esp@cenet. Method and compositions for the synthesis of BCH-189 and related compounds. WO9111186 (A1) [Online]. 1991 August 8 [cited 2010 May 22]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9111186&F=0&QPN=WO9111186

• 137.

  European Patent Office: esp@cenet. Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-Yl)-1,3- oxathiolane. WO9214743 (A2) [Online]. 1992 Sep3 [cited 2010 May 22]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9214743&F=8&QPN=WO9214743

• 138.

  Knowledge Ecology International. [Online]. [cited 2010 May 22]. Available from: http://www.keionline.org/index.php?option=com_content&task=view&id=23&ltemid=5

• 139.

  Gilead Sciences. Gilead Sciences and Royalty Pharma announce $525 million agreement with Emory University to purchase royalty interest for emtricitabine [Online]. Foster City (CA): Gilead Sciences, Inc.; 2005 Jul 18 [cited 2010 May 22]. Available from: http://www.gilead.com/pr_731707

• 140.

  Gilead Sciences. Partnerships [Online]. 2010 [cited 2010 May 22]. Available from: http://www.gilead.com/access_partnerships

• 141.

  European Patent Office: esp@cenet. HIV replication inhibiting pyrimidines. WO0027825 (A1) [Online]. 2000 May 18 [cited 2010 May 22]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO0027825&F=0&QPN=WO0027825

• 142.

  Indian Patent Office. HIV replication inhibiting pyrimidines, Patent No. 204028. 2007 May 25 [cited 2011 June 15].

• 144.

  Indian Patent Office. HIV Inhibiting 2-(4-Cyanophenyl)-6-Hydroxylaminopyrimidines, 4697/ DELNP/2007. 2007 August 17 [cited 2011 June 15].

• 145.

  Indian Patent Office. HIV Inhibiting 2-(4-Cyanophenylamino) Pyrimidine Derivatives 4831/DELNP/2007. 2007 June 06 [cited 2012 May 14].

• 146.

  European Patent Office: esp@cenet. Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors. WO9933815 (A1) [Online]. 1999 Jul 8 [cited 2010 May 22]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9933815&F=1&QPN=WO9933815

• 147.

  Ouyang H. Case study: fosamprenavir: a prodrug of amprenavir. In: Stella VJ, Borchardt RT, Hageman MJ, et
  al. Biotechnology: pharmaceutical aspects. [Online] New York: SpringerLink; 2008. [cited 2012 June 14] Available from: http://www.springerlink.com/content/p05m154851103010/?p=0eb3f6f80327487a885192b60b204bb8&pi=8

• 148.

  European Patent Office: esp@cenet. Calcium (3S) Tetrahydro-3-Furanyl(1S,2R)-3-[(4-Aminophenyl) Sulfonyl Amino]-1-Benyzl-2-(Phosphonooxy) Propylcarbamate.WO 0004033 (A1). [Online]. 2000 Jan 27. [cited 2010 May 22]. Available from: http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=20000127&CC=WO&NR=0004033A1&KC=A1

• 149.

  World Health Organization. Prioritizing second-line antiretroviral drugs for adults and adolescents: a public health approach: report of a WHO working group meeting. [Online] WHO HIV Department, Geneva, 21-22 May 2007. Geneva: WHO; 2007. [cited 2012 June 15] Available from: http://www.who.int/hiv/pub/meetingreports/Second_Line_Antiretroviral.pdf

• 150.

  African Intellectual Property Organization. History of OAPI [Online] [cited 2010 May 22]. Available from: http://www.oapi.wipo.net/en/OAPI/historique.htm

• 151.

  Indian Patent Office. IN240930 – Prodrugs of Aspartyl protease inhibitors [online] [cited 2011, June 23] Available from: http://www.ipindiaonline.gov.in/patentgrantedSearch/S(3xofl4y2uec51p55pf2k4hqk))/displayApplication.aspx?application_number=2210/CAL/1998Z

• 152.

  Patent Daily (Pharma). Fosamprenavir – opposition – India. 2011 September 18. [cited 2012 May 2]. Available from: http://patentdaily.wordpress.com/2011/09/18/fosamprenavir/

• 153.

  European Patent Office: esp@cenet. HIV protease inhibitors useful for the treatment of AIDS. WO9309096 (A1) [Online]. 1993 May 13 [cited 2010 May 22]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9309096&F=8&QPN=WO9309096

• 154.

  GlaxoSmithKline Annual Report 2010: Do more, feel better, live longer. [Online] Brentford (UK): GlaxoSmithKline; 2011 Mar. [cited 2012 June 7] Available from: http://www.gsk.com/investors/reps10/GSKAnnual-Report-2010.pdf

• 155.

  GlaxoSmithKline Annual Report 2011: Do more, feel better, live longer. [Online] Brentford (UK): GlaxoSmithKline; 2012 Mar. [cited 2012 June 7] Available from: http://www.gsk.com/investors/reps11/GSKAnnual-Report-2011.pdf

• 156.

  European Patent Office: esp@cenet. Substituted -1,3-oxathiolanes with antiviral properties. EP0382526 (A2) [Online].1990 August 16 [cited 2010 May 22]. Available from: http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP0382526&F=0

• 157.

  Gazette Journal, Thomson Reuters Science. [Online] 2002. Available from: http://scientific.thomsonreuters.com/media/cdjournals/gazettenews/2002/CPG_News_0224.prf

• 158.

  European Patent Office: esp@cenet. Crystalline oxathiolane derivatives. EP0517145 (A1) [Online]. 1992 Dec 09 [cited 2010 May 22]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=EP0517145&F=0&RPN=WO9221676&DOC=deb45b02a96922db93500ecb934bf2c269&QPN=WO9221676

• 159.

  European Patent Office: esp@cenet. Pharmaceutical compositions containing lamivudine. IL131917 (A) [Online].2001 Jan 11 [cited 2010 May 22]. Available from: http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=20010111&CC=IL&NR=131917A&KC=A

• 160.

  Abbott. Annual Report 2011: A promise for life. [Online] Abbott; 2011 March. [cited 2012 June 6] Available from: http://www.abbottinvestor.com/phoenix.zhtml?c=94004&p=irol-proxy

• 161.

  Abbott. Abbott Reports Double-Digit Sales and Ongoing Earnings Growth in Fourth Quarter; Issues Ongoing Earnings Outlook for 2011. [Online]. Abbot Park (IL, USA): 2011 Jan 26. [cited 2011 Apr 7]. Available from: http://www.abbott.com/PressRelease/2011Jan26.htm

• 162.

  Abbott. Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Issues Strong Earnings Outlook for 2010. [Online]. Abbot Park (IL, USA): 2010 Jan 27. [cited 2010 May 22]. Available from: http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0816.htm

• 163.

  Abbott Laboratories Highlights from recent Management Meetings, North America Equity Research, 6 July 2005.

• 164.

  Abbott. Abbott reports 16.1 percent sales growth in fourth quarter [Online]. Abbott Park (IL, USA): Abbott; 2008 Jan 23 [cited 2010 May 22]. Available from: http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0568.htm

• 165.

  European Patent Office: esp@cenet. Retroviral protease inhibiting compounds. WO9721685 (A1) [Online]. 1997 Jun 19 [cited 2010 May 22]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9721685&F=0&QPN=WO9721685

• 166.

  European Patent Office: esp@cenet. Pharmaceutical composition. WO9822106 (A1) [Online]. 1998 May28 [cited 2010 May 22]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9822106F=1&QPN=WO9822106

• 167.

  European Patent Office: esp@cenet. Solid pharmaceutical dosage form. WO2005039551 (A2) [Online]. 2005 May
  6 [cited 2010 May 22]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO2005039551&F=0&QPN=WO2005039551

• 168.

  Crystalline pharmaceutical, IN/PCT/2002/01243/MUM A [Online] 2005 March 4 [cited 2011 June 16] Available from: http://india.bigpatents.org/apps/3gnRsvmV

• 169.

  Indian Patent Office. Polymorph of ritonavir, 1638/ MUMNP/2007. 2007 November 23 [cited 2011 June 16].

• 170.

  Indian Patent Office. Polymorph of a Pharmaceutical, IN/PCT/2001/00018/MUM. 2001 September 15 [cited 2011 June 16].

• 171.

  Indian Patent Office. Ploymorph of Ritonavir, 676/MUMNP/2007. 2008 February 15 [cited 2011 June 16].

• 172.

  Indian Patent Office. Polymorph of Ritonavir, 677/MUMNP/2007. 2008 February15 [cited 2011 June 16].

• 173.

  Indian Patent Office. Solid Pharmaceutical Dosage Form,339/MUMNP/2006. 2007 June 29 [cited June 17].

• 174.

  A Solid Pharmaceutical Dosage Formulation, 6733/DELNP/2007 [Online] 2007 September 21 29 [cited June 17]
  Available from: http://india.bigpatents.org/apps/3rvGdPIO

• 175.

  Initiative for Medicines, Access and Knowledge (I-MAK). Lopinavir/ritonavir [Online]. [2009] [cited 2010 May 20]. Available from: http://www.i-mak.org/lopinavirritonavir/

• 176.

  Initiative for Medicines, Access and Knowledge. Rejection Decision for Patent Application no. 339/MUMNP/2006 [Online] 2010 December 30 [cited 2011 June 17] Available from: http://www.i-mak.org/storage/339.MUMNP.2006_Decision%20copy.pdf

• 177.

  Official Letter by Abbott on abandonment of divisional application 726/MUMNP/2009. 2011 January 29 [cited 2011 June 16].

• 178.

  India Patent Office. Patent status of application no. 2474/DELNP/2009 as abandoned [Online] 2009 July 31 [cited 2011 June 16] Available from: http://www.ipindia.nic.in/ipirs1/patentsearch.htm

• 179.

  Initiative for Medicines, Access and Knowledge. Rejection Decision for Patent Application no. IN/PCT/2002/01243/MUM [Online] 2010 September 27 [cited 2011 June 16] Available from: http://www.i-mak.org/storage/IPO%20Decision%20IN-PCT-2002-1243-MUM%20Order.pdf

• 180.

  Claims a particular polymorph and process of preparation of the same. Matrix has filed a patent opposition on it.

• 181.

  Abandonment Letter by Abbott for patent application for Ritonavir Polymorph, 676/MUMNP/2007 and 677/MUMNP/2007 [Online] 2011 March 1[cited 2012 May 10] Available from: http://www.scribd.com/doc/92955345/abandonmentLetter-WO-0004016-applications676-677

• 182.

  A Solid Pharmaceutical Dosage Formulation, 6733/DELNP/2007 [Online] 2007 September 21 29 [cited June 17]
  Available from: http://india.bigpatents.org/apps/3rvGdPIO

• 183.

  Process and Intermediates for preparing Retroviral Protease Inhibitors, 259/MUMNP/2003 A [Online] 2005 March 4 [cited 2011 June 16] Available from: http://india.bigpatents.org/apps/2ElDpHs0

• 184.

  Thailand. Ministry of Public Health and National Health Security Office. Facts and evidences on the 10 burning issues related to the Government use of patents on three patented essential drugs in Thailand: document to support strengthening of social wisdom on the issue of drug patent. [online] Ministry of Public Health and National Health Security; 2007. [cited 2011, June 20] Available from: http://www.moph.go.th/hot/White%20Paper%20CL-EN.pdf

• 185.

  Personal communication with Kannikar Kijtiwatchakul, MSF Thailand. Price quoted in Thai Baht converted to US$ through www.oanda.com [cited 2009 Sep 21].

• 186.

  Hasenclever L, Lopes R, Chaves GC, et al. O instituto de patentes Pipeline e o acesso a medicamentos: aspectos econômicos e jurídicos deletérios à economia da saúde (The pipeline mechanism and Access to medicines: economic and juridical aspects). [Online] Rev. Direito Sanit. vol.11 no2 2010 Out. [cited 2012 June 1] Available from: http://www.revistasusp.sibi.usp.br/scielo.php?pid=S1516-41792010000300007&script=sci_arttext

• 187.

  Médecins Sans Frontières. Are Brazilian Pipeline Patents Constitutional? [Online]. 2010 April 21. [cited 2010 May 20]. Available from: http://www.msfaccess.org/main/access-patents/arebrazilianpipeline-patentsconstitutional/

• 188.

  Intellectual Property Watch. Brazil HIV Drug Patent Ruling Allows Generics, Sends Pipeline Process Into Doubt. [Online] 2012 March 21. [cited 2012 June 19] Available from: http://www.ip-watch.org/2012/03/21/brazil-hiv-drug-patentruling-allows-generics-sends-pipelineprocess-into-doubt/

• 189.

  Intellectual Property Watch. Brazil HIV Drug Patent Ruling Allows Generics, Sends Pipeline Process Into Doubt. [Online] 2012 March 21. [cited 2012 June 19] Available from: http://www.ip-watch.org/2012/03/21/brazil-hiv-drug-patentruling-allows-generics-sends-pipelineprocess-into-doubt/

• 190.

  REBRIP, Grupo del Trabalho sobre Propriedade Intelectual. Forma Farmacêutica De Dosagem Sólida. [Online] 2004 August 23. [cited 2012 June 8] Available from: http://www.deolhonaspatentes.org.br/media/file/subsidio_versao_final_08_11.pdf

• 191.

  European Patent Office: esp@cenet. Forma de dosagem farmacêutica sólida. BRPI0413882 (A) 2006-10-24 [cited 2012 May 2]. Available from: http://worldwide.espacenet.com/publicationDetails/originalDocument?CC=BR&NR=PI0413882A&KC=A&FT=D&date=20061024&DB=EPODOC&locale=en_EP

• 192.

  Grupo del Trabalho sobre Propriedade Intelectual (Brazilian Working Group on Intellectual Property (GTPI). INPI determines priority examination for HIV/AIDS medicines. [Online] 2011 15December [cited 2012 May 29] Available from: http://www.deolhonaspatentes.org.br/default.asp?site_Acao=mostraPagina&paginaId=891&acao=blog&blogId=346

• 193.

  Public Citizen. Global Kaletra Campaign. [Online]. 2011 November 10 [cited 2012 May 4]. Available from: http://www.citizen.org/Kaletra-campaign

• 194.

  Boehringer Ingelheim. Annual report 2007. [Online] Ingelheim: Boehringer Ingelheim; 2008 [cited 2010 May 22]. Available from: http://www.boehringeringelheim.nl/content/dam/internet/opu/nl_NL/documents/downloads/annual_report_2007.pdf

• 195.

  Boehringer Ingelheim. Annual report 2004. Ingelheim: Boehringer Ingelheim; 2005. [cited 2010 May 22].

• 196.

  Boehringer Ingelheim. Annual report 2005. [Online] Ingelheim: Boehringer Ingelheim; 2006 [cited 2010 May
  22]. Available from: http://mediapool.boehringer-ingelheim.co/index.php?id=18tx_mediadb_pi1%5Bcat%5D=128&cHash=f3930e00d3

• 197.

  Boehringer Ingelheim. Annual report 2006. [Online] Ingelheim: Boehringer Ingelheim; 2007 [cited 2010 May 22]. Available from: http://www.boehringeringelheim.nl/content/dam/internet/opu/nl_NL/documents/downloads/annual_report_2006.pdf

• 198.

  European Patent Office: esp@cenet. 5,11-Dihydro-6H-dipyrido[3,2-b:2’,3’-e] [1,4] Diazepines and their use in the prevention or treatment of HIV infection. EP0429987 (A2) [Online]. 1991 Jun 5 [cited 2010 May 22]. Available from: http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP0429987&F=8

• 199.

  European Patent Office: esp@cenet. Pharmaceutical suspension comprising nevirapine hemihydrate. WO9909990 (A1) [Online]. 1999 Mar 4 [cited 2010 May 22]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9909990&F=0&QPN=WO9909990

• 200.

  European Patent Office: esp@cenet. Extended release formulation of nevirapine. AU2008262031 (A1) [Online]. 2008 Dec 18 [cited 2010 May 22]. Available from: http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_V3&FT=D&date=20081218&CC=AU&NR=2008262031A1&KC=A1

• 201.

  World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants: Recommendations for a public health approach – 2010 revision. [online] Geneva, 2010. [cited 2012, May 22] Available from: www.who.int/hiv/pub/mtct/PMTCTfactsheet/en/index.html

• 202.

  Pharmaceutical suspension comprising nevirapine hemihydrate 2485/DEL/1998 [Online] 1998 August 24 [cited 2012 May 14] Available from: http://www.scribd.com/doc/93216827/Nevi-Rapine-Hemihydrate-Specification-2485-DEL-1998

• 203.

  Indian Network of Positive People and Positive Women’s Network. Patent Pre grant Opposition filed against 2485/DEL/1998 [Online] 2005 March 04 [cited 2012 May 14] Available from: http://www.scribd.com/doc/93216923/2485-Del-1998-Pre-Grant-Opposition-INP-and-PWN

• 204.

  Rejection order by Indian patent office for 2485/DEL/1998 [Online] 2007 august 31 [cited 2012 May 14] Available from: http://www.scribd.com/doc/93216965/2485-DEL-1998-Patent-Office-Rejection

• 205.

  Lawyers Collective. Patent for Nevirapine Rejected. 2007 Aug 31. [cited 2010 May 22].

• 206.

  World Intellectual Property Organization. Extended Release Formulation of Nevirapine, WO/2008/154234 [Online] 2008 December 18 [cited 2011 June 18] Available from: http://www.wipo.int/pctdb/en/fetch.jsp?lang=eng&dbselect=pct&server_type=1910&sort=41317401key&type_field=256&idb=0&idoc=1641915&c=10&element_set=b&result=1&total=1&start=1&disp=25&form=sep0/hitnum,beng,dp,mc,an,pa,absumengsearch_ia=us2008065705&query=%28wo%2fwo2008154234%29

• 207.

  India Patent Office. Extended Release Formulation Of Nevirapine 4724/DELNP/2009 [Online] 2010 March 5 [Cited 2011 June 20] Available from: http://124.124.220.66/patentpublishedsearch/(X(1)S(aqrrvd2vke25s5ulxsuodyvf))/publishApplicationNumber.aspx?application_number=4724/DELNP/2009&AspxAutoDetectCookieSupport=1

• 208.

  Merck. 2011 Form 10-K. [Online] Whitehouse Station (NJ). Merck & Co., Inc. 2012 Feb 28. [cited 2012 April 26]. Available from: http://www.merck.com/investors/financials/home.html

• 209.

  Merck and Co. 2010 Form 10K: annual report. [Online] Whitehouse Station (NJ, USA): Merck and Co, Inc.; 2011 Feb 28. [cited 2011 Apr 7]. Available from: http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9ODM1MDV8Q2hpbGRJRD0tMXxUeXBlPTM=&t=1

• 210.

  Merck and Co. 2009 Form 10K: annual report. [Online] Whitehouse Station (NJ, USA): Merck and Co, Inc.; 2010 Mar 1. [cited 2010 May 22]. Available from: http://www.merck.com/finance/annualreport/ar2009/pdf/Merck_form_10-k.pdf

• 211.

  Merck and Co. 2008 Form 10-K: annual report. [Online] Whitehouse Station (NJ, USA): Merck and Co, Inc.; 2009 [cited 2010 May 22]. Available from: http://media.corporate-ir.net/media_files/irol/73/73184/MRKForm10K2008final.pdf

• 212.

  European Patent Office: esp@cenet. N-Substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase.WO03035077 (A1) [Online]. 2003 May 1 [cited 2010 May 22]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO03035077&F=0&QPN=WO03035077

• 213.

  European Patent Office: esp@cenet. Potassium salt of an HIV intergrase inhibitor. WO2006060712 (A2) [Online]. 2006 Jun 8 [cited 2010 May 22]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO2006060712&F=0&QPN=WO2006060712

• 214.

  World Intellectual Property Organization. Potassium Salt of an HIV Integrase Inhibitor, WO2006060730 [Online] 2006 June 8 [cited 2011 June 17] Available from: http://www.wipo.int/patentscope/search/en/WO2006060730

• 215.

  World Intellectual Property Organization.Potassium Salt of an HIV Integrase Inhibitor, WO2006060712 [Online] 2006 June 8 [cited 2011 June 17] Available from: http://www.wipo.int/patentscope/search/en/WO2006060712

• 216.

  World Intellectual Property Organization. N−Substituted Hydroxypyrimidinone Carboxamide Inhibitors of HIV Integrase, WO2003035077 [Online] 2003 May 1 [cited 2011 June 17] Available from: http://www.wipo.int/patentscope/search/en/WO2003035077

• 217.

  India Patent Office. N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors of HIV Integrase, Patent No. 212400 [Online] 2008 Februrary 15 [cited 2011 June 17] Available from: http://www.ipindiaonline.gov.in/patentgrantedSearch/(S(25ngpj3miuvkn3e5udaa0x55))/displayApplication.aspx?application_number=868/CHENP/2004

• 218.

  India Patent Office. Potassium Salt of an HIV Integrase Inhibitor, 4187/DELNP/2007 [Online] 2007 August 31 [cited 2011 June 17] Available from: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=4187/DELNP/2007

• 219.

  Bonanno L. Governo negocia com Merck transferência de conhecimento para a produção nacional do raltegravir (Government negotiates technology transfer agreement with Merck for national production of raltegravir). [Online] Agência de Notícias da AIDS 2010 Set 29. [cited 2012 June 5] Available from: http://www.agenciaaids.com.br/site/noticia.asp?id=15713

• 220.

  Working Group on Intellectual Property GTPI/Rebrip [Online]. 2011 Apr. Available from: http://www.deolhonaspatentes.org.br/media/file/Notas%20GTPI%20-%202011/Carta%20GTPI_Preocupa%C3%A7%C3%B5es.pdf

• 221.

  Information provided by Brazilian Department on DSTs/AIDS and Hepatitis(April 2011).

• 222.

  Money Control. Cipla tells Merck your anti-AIDS drug too costly in India. [online] 2011 Apr 07 [cited 2011 June 16] Available from: http://www.moneycontrol.com/news/business/cipla-tells-merck-your-anti-aidsdrugtoocostlyindia_533783-1.html

• 223.

  Abbott Laboratories Highlights from Recent Management Meetings, North America Equity Research, 6th July 2005.

• 224.

  European Patent Office: esp@cenet. Protease inhibiting compounds. WO9414436 (A1) [Online]. 1994 Jul 7
  [cited 2010 May 22]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9414436&F=1&QPN=WO941443

• 225.

  European Patent Office: esp@cenet. Pharmaceutical composition. WO9822106 (A1) [Online]. 1998 May 28 [cited 2010 May 22]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9822106&F=1&QPN=WO9822106

• 226.

  European Patent Office: esp@cenet. Polymorph of a pharmaceutical. WO0004016 (A2) [Online]. 2000 Jan 27 [cited 2010 May 22]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO0004016&F=1&QPN=WO0004016

• 227.

  European Patent Office: esp@cenet. Improved Pharmaceutical Formulations. WO 0152821 (A1). [Online]. 2001 Jul 26. [cited 2010 May 20]. Available from: http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=20010726&CC=WO&NR=0152821A1&KC=A1

• 228.

  Highlights of prescribing information, Norvir (retonavir) [Online] Abbot Laboratories, 2010, April [cited 2011, June 21] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020659s050,022417s001lbl.pdf

• 229.

  World Health Organization: Short-Term priorities for antiretroviral drug optimization. Meeting Report. [Online] London, UK. 18-19 April 2011. [cited 2012 June 6] Available from: http://whqlibdoc.who.int/publications/2011/9789241501941_eng.pdf

• 230.

  World Intellectual Property Organization, Patent Landscape Report on Ritonavir [Online] 2011 October [cited 2012 May 2] Available from: http://www.wipo.int/freepublications/en/patents/946/wipo_pub_946.pdf

• 231.

  India Patent Office. Polymorph of ritonavir, 1638/MUMNP/2007 [Online] 2007 November 23 [cited 2011 June 16] Available from: http://124.124.220.66/patentpublishedsearch/(X(1)S(1g02djmey4tz5l45bz1m01qd))/publishApplicationNumber.aspx?application_number=1638/MUMNP/2007&AspxAutoDetectCookieSupport=1

• 232.

  Polymorph of a Pharmaceutical, IN/PCT/2001/00018/MUM [Online] 2001 September 15 [cited 2011 June 16]
  Available from: http://india.bigpatents.org/apps/4rHoD3qA

• 233.

  India Patent Office. Ploymorph of Ritonavir, 676/MUMNP/2007 [Online] 2008 February 15 [cited 2011 June 16] Available from: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=676/MUMNP/2007

• 234.

  India Patent Office. Polymorph of Ritonavir, 677/MUMNP/2007 [Online] 2008 February15 [cited 2011 June 16] Available from: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=677/MUMNP/2007

• 235.

  Rejection Order of Patent Application No. /PCT/2001/00018/MUM [Online] 2011 April 13 [cited 2011 June 23] Available from: http://www.i-mak.org/storage/IPO%20Decision%20IN.PCT.2001.00018.MUM_us%2015.pdf

• 236.

  Official Letter by Abbott on abandonment of divisional applications 676/MUMNP/2007 and 677/MUMNP/2007
  [Online] 2011 January 29 [cited 2011 June 16] Available from: https://docs.google.com/viewer?a=v&pid=explorer&chrome=true&srcid=0B_rFBOOQV_1MM2YyODBjODQtNGNhNS00YmNlLTgyYTItY2MxM2M2ZGE4ZGRh&hl=en&authkey=CIShhooB&pli=1

• 237.

  Saez, C. Ecuador Grants First Compulsory Licence, For HIV/AIDS Drug. Intellectual Property Watch. [Online]. 2010 Apr 22. [cited 2010 May 22]. Available from: http://www.ip-watch.org/weblog/2010/04/22/ecuador-grantsfirstcompulsory-licence-forhivaids-drug/

• 238.

  Saez, C. Ecuador To Define Its Compulsory Licence Legislation. Intellectual Property Watch. [Online]. 2009 Nov 23. [cited 2010 May 22]. Available from: http://www.ip-watch.org/weblog/2009/11/23/ecuadorto-define-its-compulsorylicencelegislation/

• 239.

  European Patent Office: esp@cenet. Amino acid derivatives. EP0432695 (A2) [Online]. 1991 June 19 [cited 2010 May 22]. Available from: http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP0432695&F=1

• 240.

  European Patent Office: esp@cenet. Saquinavir mesylate oral dosage form. WO2005004836 (A2) [Online]. 2005 Jan 20 [cited 2010 May 22]. Available from: http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_V3&FT=D&date=20050120&CC=WO&NR=2005004836A2&KC=A2

• 241.

  India Patent Office. Pharmaceurical Composition Comprising A Proteinase Inhibitor, Patent No. 200832 [Online] 2007 Februray 23 [cited 2011 June 16] Available from: http://www.ipindiaonline.gov.in/patentgrantedSearch/S(ibkxcj55xaf0hkboji5fn355))/displayApplication.aspx?application_number=910/MAS/1996

• 242.

  India Patent Office. A Process For Preparing A Pharmaceutical Composition Having Enhanced Bioavailability, Patent No. 192899 [Online] 2009 July 24 [cited 2011 June 16] Available from:
  http://www.ipindiaonline.gov.in/patentgrantedSearch/S(i53oag55550ptfmbod0anerq/displayApplication.aspx?application_number=763/MAS/2000

• 243.

  India Patent Office. Saquina Vir Mesylate Oral Dosage Form, Patent No. 227217 [Online] 2009 February 13 [cited 2011 June 16] Available from: http://www.ipindiaonline.gov.in/patentgrantedSearch/(S(ev4hfq45n4vr1i45jroeeg55))/displayApplication.aspx?application_number=86/CHENP/2006

• 244.

  European Patent Office: esp@cenet. Pharmaceutical composition comprising 3’-deoxythymidin-2’-ene(3’- deoxy-2’,3’-didehydrothymidine) in treating patients infected with retrovirUS EP0273277 (A2) [Online]. 1988 Jul 7 [cited 2010 May 22]. Available from: http://v3.espacenet.com/textdoc?DB=EPODOC IDX=EP0273277&F=8

• 245.

  Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. [Online] JAMA. 2004 Jul 14; 292(2):191-201. [cited 2012 June 21] Available from: http://www.ncbi.nlm.nih.gov/pubmed/15249568

• 246.

  Consumer Project on Technology. Stavudine (d4T) [Online]. 2006 ? [cited 2010 May 23]. Available from: http://www.cptech.org/ip/health/d4T.html

• 247.

  Gilead Sciences. 2005 Annual report: stepping up. [Online] Delaware: Gilead Sciences Inc.; 2006 [cited 2010 May 22]. Available from: http://ccbn.mobular.net/ccbn/7/1377/1472/print/print.pdf

• 248.

  Gilead Sciences. 2006 Annual report: why we’re here. [Online] Delaware: Gilead Sciences Inc.; 2007 [cited 2010 May 22]. Available from: http://www.gilead.com/AR2006/GILEAD%20AR06_final.pdf

• 249.

  European Patent Office: esp@cenet. 9-(phosponylmethoxyalkyl) adenines, the method of preparation and utilization thereof. US4808716 (A) [Online]. 1989 Feb 28 [cited 2010 May 22]. Available from: http://v3.espacenet.com/textdoc?db=epodoc&idx=us4808716&f=0&rpn=ep0206459doc=cca34af1984f08bf7c37f3b37b34dbab52&qpn=ep0206459

• 250.

  European Patent Office: esp@cenet. Nucleotide analogs. WO9804569 (A1) [Online]. 1998 Feb 5 [cited 2010 May 22]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9804569&F=8&QPN=WO9804569

• 251.

  European Patent Office: esp@cenet. Nucleotide analog composition and synthesis method. WO9905150 (A1)
  [Online]. 1999 Feb 4 [cited 2010 May 22]. Available from: esp@cenet:http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9905150&F=8&QPN=WO9905150

• 252.

  Viread (Tenofovir) [package insert]. Foster City, (CA). Gilead Sciences, Inc.; 2012.

• 253.

  Patent Opposition. Lawyers Collective: The Third Eye of the Law. http://www.lawyerscollective.org/amtc/patentopposition

• 254.

  World Intellectual Property Organization. Compositions and methods for combination antiviral therapy.
  WO/2004/064845 [Online]. 2004 Aug 5 [cited 2010 May 22]. Available from: http://www.wipo.int/pctdb/en/wo.jsp?wo=2004064845

• 255.

  Pre Grant Opposition by PLHIV Networks to Patent Application No. 2076/DEL/1997 [Online] 2006 September
  5 [cited 2011 June 18] Available from: http://indianpatentoppositions.blogspot.com/2011/06/td-opposition-andrejectionorder.html

• 256.

  Pre-Grant Opposition by Brazilian NGO and NGO Sahara to Patent Application No. 2076/DEL/1997 [Online]
  2007 [cited 2011 June 18] Available from: http://indianpatentoppositions.blogspot.com/2011/06/td-opposition-andrejectionorder.html

• 257.

  Indian Patent Office. Rejection order of Patent Application No. 2076/DEL/1997 [Online] 2009 July 30 [cited 2011 June 18] Available from: http://ipindiaonline.gov.in/decision/2076-DEL-1997-344/2076-del-1997%20cipla.pdf

• 258.

  Indian Patent Office. Rejection order of Patent Application No. 896/DEL/2002 [Online] 2009 July 30 [cited 2011 June 18] Available from: http://ipindiaonline.gov.in/decision/896-DEL-2002-340/896-del-2002%20intermed.pdf

• 259.

  Indian Patent Office. Rejection order of Patent Application No. 963/DEL/2002 [Online] 2009 March 9 [cited 2011 June 18] Available from: http://ipindiaonline.gov.in/decision/963-DEL-2002-201/intermed%20decision.pdf

• 260.

  Indian Patent Office. Rejection order of Patent Application No. 3383/DELNP/2005 [Online] 2009 March 25
  [Cited 2011 June 18] Available from: http://ipindiaonline.gov.in/decision/3383-DELNP-2005-285/3383-delnp-2005.pdf

• 261.

  Indian Patent Office. Nucleotide Analogs, 602/DEL/2007 [Divisional Application to 896/DEL/2002] [Online] 2007 August 03 [cited 2011 June 18]. Available from: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=602/DEL/2007

• 262.

  Indian Patent Office. A Compound, 1135/DEL/2007 [Divisional Application to 896/DEL/2002]. [Online]. 2007
  August 31. [cited 2011 June 18]. Available from: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=1135/DEL/2007. There are three divisional applications: – 1135/DEL/2007; 2100/DEL2007; 2256/DEL/2009

• 263.

  Indian Patent Office. A Compound, 1135/DEL/2007 [Divisional Application to 896/DEL/2002]. [Online]. 2007 August 31. [cited 2011 June 18]. Available from: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=1135/DEL/2007

• 264.

  Indian Patent Office. 6665/DELNP/2008 (Divisional Application to 3383/DELNP/2005). [Online] 2008 October
  24 [cited 2011June 18] Available from: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=6665/DELNP/2008

• 265.

  Knowledge Ecology International. KEI asks FTC to Investigate Gilead Effort To Control Market For AIDS Drugs Ingredients. [Online] 2007 February 15 [cited 2012 May 30] Available from: http://keionline.org/content/view/23/1

• 266.

  The Medicines Patent Pool. Licences in the Pool: Gilead Sciences. [Online]. 2011 December [cited 2012 June 1]. Available from: http://www.medicinespatentpool.org/ing/current-licences/

• 267.

  Médecins Sans Frontières. MSF review of the July 2011 Gilead licences to the Medicines Patent Pool [Online] December 2011. [cited 2012 May 2]. Available from http://www.msfaccess.org/content/msfreview-july-2011-gilead-licences-medicinespatent-pool

• 268.

  Gilead. Gilead Expands Access Program for Medications in Developing World (Press Release) [Online] 2011July 12.[cited 2012 May 2]. Available from http://www.gilead.com/pr_1584101

• 269.

  Information provided by Brazilian Department on DSTs/AIDS and Hepatitis (2010). [cited 2010 June 1].

• 270.

  Working Group on Intellectual Property GTPI/Rebrip [Online]. 2006 Dez 01. Available from: http://www.deolhonaspatentes.org.br/media/file/Subs%C3%ADdio%20Tenofovir.pdf

• 271.

  Working Group on Intellectual Property GTPI/Rebrip [Online]. 2009 Nov 05. Available from: http://www.deolhonaspatentes.org.br/media/file/Subsidio%20Divisional%20Tenofovir.pdf

• 272.

  I-Mak. Brazilian Patent Office Rejects Gilead Divisional Application for Tenofovir Disoproxil Fumarate [Online] 2011 May 18. [cited 2012 June 6] Available from: http://www.i-mak.org/i-makblogupdates/2011/5/18/brazilian-patentofficerejects-gileads-divisional-applicati.html

• 273.

  Alves D. Governo passará a fabricar remédio contra Aids que era importado dos EUA (Government Will produce AIDS drug that used to be imported from the US)[Online] Correio Braziliense 2011 Feb 10.
  [cited 2012 May 31] Available from: http://www.correiobraziliense.com.br/app/noticia/brasil/2011/02/10/interna_brasil,237010/governo-passara-a-fabricarremedio-contraaids-que-era-importado-doseua.shtml

• 274.

  Information provided by Brazilian Department on DSTs/AIDS and Hepatitis(June 2011).

• 275.

  European Patent Office esp@cenet. Treatment of human viral infections, [Filed 1985, Sep 17]. [cited 2012, May 30]. Available from: http://worldwide.espacenet.com/publicationDetails/biblio?CC=US&NR=4724232&KC=&FT=E&locale=en_EP

• 276.

  Janssen Pharmaceutical Companies. Global Access and Partnership Program. [Online]. 2007 [cited 2012 June 19]. Available from: http://www.ip-watch.org/weblog/wp-content/uploads/2012/01/Janssen-GAPP-Stakeholder-E-Comm-21Sept1121.pdf

• 277.

  United States Food and Drug Administration. Highlights of prescribing information – Retrovir (zidovudine) [Online] US Food and Drug Administration, 2010, May. [cited 2011, June 16] Available from:
  http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019655s049lbl.pdf

• 278.

  India. Government. Ministry of commerce and industry. Patent office, Delhi branch. Decision regarding representation U/S 25 (1) filed by M/S lntermed Labs Pvt. Ltd, Bangalore, (KS) in respect of application No 896/Del/2002 and hearing held on 18/09/2008. 2009 Jul 30 [cited 2010 May 23]. Available from:
  http://www.i-mak.org/storage/896.DEL.2002_Intermed%20Labs.PDF

• 279.

  The PharmaLetter. Cipla patents Triomune in South Africa. [Online]. 2004 July 19 [cited 2010 May 30]. Available from: http://www.thepharmaletter.com/file/46079/cipla-patents-triomune-in-southafrica.html

• 280.

  World Intellectual Property Organization. Compositions and methods for combination antiviral therapy. WO/2004/064845 [Online]. 2004 Aug 5 [cited 2010 May 22]. Available from: http://www.wipo.int/pctdb/en/wo.jsp?wo=2004064845

• 281.

  British HIV Association.(BHIVA) Guidelines for the management of HIV infection in pregnant women 2012.
  [online] London, 2012. [cited 2012, May 9] Available from: http://www.bhiva.org/PregnantWomen2012.aspx

• 282.

  Drug Patent Watch. Search for Tradename: Atripla. 2010. [cited 2012 May 30]. Available from: http://drugpatentwatch.com/ultimate/preview/tradename/index.php?query=Atripla

• 283.

  Merck To Register, Lower Cost Of Antiretroviral Atripla In Developing Countries. Medical News Today.
  [Online] 23 February 2007. [cited 2012, May 30] Available from: http://www.medicalnewstoday.com/releases/63612.php

• 284.

  India. Office of Controller General of Patents Designs, and Trademarks. 9527/ DELNP/2007. Indian Patent Information Retrieval System. [Online] India, 2011, June [cited 2011, June 22] Available from:
  http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=9527/DELNP/2007

• 285.

  India. Office of Controller General of Patents Designs, and Trademarks. 9661/ DELNP/2007. Indian Patent Information Retrieval System. [Online] India, 2011, June [cited 2011, June 22] Available from: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=9661/DELNP/2007

• 286.

  India. Office of Controller General of Patents Designs, and Trademarks. Application Number 9661/ DELNP/2007. Stable Fixed-Dose Unitary Formulations Containing tenofovir, a surfactant, efavirenz and emtricitabine. [Online]. 2007 Dec 13. [cited 2010 May 22]. Intellectual Property India. Available from:
  http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=9661/DELNP/2007

• 287.

  European Patent Office: esp@cenet. Pharmaceutical combination.WO2007068934 (A2) [Online]. 2007 Jun
  21 [cited 2010 May 22]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO2007068934&F=0&QPN=WO2007068934

• 288.

  Ford N, Calmy A, Mofenson L. Safety of efavirenz in first-trimester of pregnancy: an updated systematic review and metaanalysis. AIDS 2011. 25:2301–2304.

• 289.

  European Patent Office: esp@cenet. Antiviral combinations containing nucleoside analogs. WO9220344 (A1)
  [Online]. 1992 Nov 26[cited 2010 May 23]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9220344&F=0&QPN=WO9220344

• 290.

  European Patent Office: esp@cenet. Pharmaceutical compositions containing lamivudine and zidovudine. WO9818477 (A2) [Online]. 1998 May 7 [cited 2010 May 23]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9818477&F=0&QPN=WO9818477

• 291.

  India Patent Office/Patent Search. Pharmaceutical Composition, 2044/CAL/1997 [Online] 2005 March 11 [Cited 2011 June 20] Available from: http://ipindia.nic.in/ipirs1/patentsearch.htm

• 292.

  Complete specification of the Application 2044/CAL/1997 [cited 2011 June 20] Available from: http://crocodoc.com/1RuvPUO

• 293.

  Pre Grant Opposition by PLHIV Networks to Patent Application No. 2044/CAL/1997 [Online] [Cited
  2011 June 20] Available from: http://indianpatentoppositions.blogspot.com/2011/06/azt3tc-opposition.html

• 294.

  Open Letter from GSK promising withdrawal of AZT/3TC FDC [Online] 2006 August 9 [Cited 2011 June 20] Available from: http://indianpatentoppositions.blogspot.com/2011/06/azt3tc-opposition.html

• 295.

  European Patent Office: esp@cenet. Pharmaceutical combinations comprising lamivudine, zidovudine and efavirenz for treating viral infections. WO2004089382 (A1) [Online]. 2004 Oct 21 [cited 2010 May 23]. Available from: http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO2004089382&F=8&QPN=WO2004089382

• 296.

  Unnikrishnan C.H. GSK withdraws trizivir patent application ‘in public interest’. livemint.com and The Wall Street Journal 2007 Oct 10 [cited 2010 May 23]. Available from: http://www.livemint.com/2007/10/10005826/GSKwithdraws-Trizivir-patent.html

• 297.

  Knowledge Ecology International. Canada’s Intervention to TRIPS Council: Experience using the System (Apotex-Rwanda Case). [Online] 2010 October 27 [cited 2012 May 6]. Available from:http://keionline.org/node/1000

• 298.

  World Trade Organization: TRIPS and public health – dedicated webpage for notifications. [Online] 2010 [cited 2010 May 23]. Available from: www.wto.org/english/tratop_e/trips_e/public_health_e.htm

• 299.

  Médecins Sans Frontières. Neither expeditious, nor a solution: the WTO August 30th decision is unworkable: an illustration through Canada’s Jean Chrétien pledge to Africa. [Online] Geneva/Montréal 2006 Aug. [cited 2012 May 28] Available from: http://www.msfaccess.org/fileadmin/user_upload/medinnov_accesspatents/WTOaugustreport.pdf